Relora (Magnolia + Phellodendron).

Magnolia officinalis bark is one of the two barks in this blend, contributing honokiol and magnolol. A separate magnolia product adds to the same constituent intake.

The Phellodendron amurense bark in this blend contains berberine as a principal alkaloid. Taking a berberine product alongside stacks the same alkaloid, including its CYP3A4 inhibition.

Honokiol and magnolol act as positive allosteric modulators at GABA-A receptors while theanine works largely through glutamate receptor antagonism and alpha wave activity. The two calming routes are separate and are commonly formulated together.

This blend's magnolia lignans modulate the GABA-A receptor rather than binding the orthosteric site, so an agonist and a modulator act on one channel from two positions. Sedative effect can be additive.

Valerian constituents also modulate GABA-A receptors. Combining two GABA-A modulators produces additive drowsiness, which is worth accounting for in daytime formulas.

Kavalactones are also GABA-A positive modulators. The sedative effect of the two together is additive rather than complementary.

Phosphatidylserine blunts the cortisol rise to acute stress through a membrane signalling route, while this blend acts on GABAergic tone. They are long-standing companions in evening and stress formulas.

Ashwagandha withanolides moderate the hypothalamic-pituitary-adrenal response while this blend works at the receptor level on GABAergic tone. The pairing covers two different points on the same axis.

Magnesium blocks the NMDA channel at rest and the glycine carrier is itself an inhibitory neurotransmitter. Both sit on the inhibitory side of the same balance this blend modulates.

Melatonin acts on circadian timing through MT1 and MT2 receptors, a mechanism unrelated to GABA-A modulation. The two are commonly paired so that timing and calming are covered separately.

Glycine is itself an inhibitory neurotransmitter at its own receptor and at the glycine site of the NMDA receptor, working on a different channel from the GABA-A modulation that magnolia lignans contribute. Stacked in an evening formulation the two inhibitory inputs add up. That is the pairing's rationale and also the reason to keep total evening load conservative.

Magnesium sits in the NMDA receptor pore as a voltage-dependent block and supports GABA-A signalling, so it reduces excitatory tone from a direction the magnolia lignans do not cover. Evening formulations built on Relora commonly carry it for that reason. The biochemistry is settled; the combination itself has not been trialled.

Pyridoxal 5-phosphate is the cofactor that glutamate decarboxylase needs to make GABA from glutamate. A formulation aiming at GABAergic tone depends on that step being supplied. This is textbook cofactor biochemistry and requires no combination study.

Tryptophan is hydroxylated to 5-HTP and decarboxylated to serotonin, which is the substrate for melatonin synthesis at night. That route is entirely separate from the receptor modulation attributed to magnolia lignans. Pairing them covers two independent arms of evening physiology.

5-HTP bypasses tryptophan hydroxylase, the rate-limiting step, and is decarboxylated directly to serotonin. In an evening stack it supplies precursor while the botanical fraction works on receptor tone. Combining several serotonergic and GABAergic inputs raises total sedative load, which is worth stating plainly.

Passiflora flavonoids including chrysin are described as positive modulators at GABA-A, the same receptor family that honokiol acts on. Two positive modulators at one receptor complex are additive rather than complementary. Formulations using both should account for that overlap rather than count it twice.

Melissa officinalis constituents inhibit GABA transaminase, the enzyme that clears GABA, which raises available transmitter rather than modulating the receptor. That is a different point in the same pathway from the magnolia lignans. The mechanism is described in the pharmacology literature; the pairing itself is formulation practice.

Chamomile's apigenin binds the benzodiazepine site of GABA-A with low affinity, overlapping with the receptor complex honokiol modulates. The two are additive on the same target. Read the pairing as reinforcing one mechanism rather than adding a second.

Isolated apigenin occupies the same receptor site as the chamomile fraction it comes from and overlaps with magnolia lignan activity at the GABA-A complex. Stacking them raises occupancy at one target. Established receptor pharmacology, with no human combination data on the pair.

Rhodiola is used for daytime alertness and carries a mildly stimulating profile, while Relora is positioned around evening calm and cortisol rhythm. Combining them in one capsule pushes in two directions at once, which is why formulators usually split them across morning and evening doses. Timing is the practical point rather than an interaction to avoid.

Caffeine blocks adenosine receptors and raises arousal, working against the sedative direction of a GABA-A positive modulator. Taken together each blunts the other's intended effect on alertness. This is settled pharmacology and the reason the two are separated by time of day rather than blended.

Berberine-type alkaloids from Phellodendron and silymarin flavonolignans both engage CYP3A4 and P-glycoprotein handling in the gut wall and liver. Co-dosing can shift exposure of either partner in a direction that has not been quantified for this pair. Read it as a spacing consideration.

Zinc is an allosteric modulator at both GABA-A and NMDA receptors and its direction depends on subunit composition. That makes it a background variable in any formulation built on GABAergic tone rather than a straightforward additive partner. Mechanistic grounding, no combination data.

Inositol feeds the phosphatidylinositol second-messenger cycle that sits downstream of several monoamine receptors, a level below the receptor modulation attributed to magnolia lignans. Evening formulations pair the two on that reasoning. The rationale is mechanistic and the combination is untested.

Oxidised metabolites of magnolol, honokiol and berberine are handled in part by glutathione conjugation before excretion. A formulation carrying both botanical fractions draws on that pool. The relationship is metabolic handling rather than an added effect.